Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

In the double-blind, randomized PROHEAR-Study, patients with testicular cancer receive transtympanic injections of ACOU085 in one ear and a placebo in the contralateral ear prior to each chemotherapy cycle, as such each patient serves as his own control. The PROHEAR-Study is being conducted at major university clinics across Germany and has been formally endorsed by the Study Group of the German Society of Otorhinolaryngology (DSZ-HNO). In the double-blind, randomized PROHEAR-Study, patients...

In the double-blind, randomized PROHEAR-Study, patients with testicular cancer receive transtympanic injections of ACOU085 in one ear and a placebo in the contralateral ear prior to each chemotherapy cycle, as such each patient serves as his own control. The PROHEAR-Study is being conducted at major university clinics across Germany and has been formally endorsed by the Study Group of the German Society of Otorhinolaryngology (DSZ-HNO).

"The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

About Acousia Therapeutics GmbH

Acousia Therapeutics GmbH is a privately held, clinical-stage biotech company based in Tübingen, Germany. The company is dedicated to the identification of small molecules for the effective prevention and treatment of different hearing loss etiologies. Acousia is focused on the development of proprietary drug candidates, which are designed to affect the sensory outer hair cells (OHC) in the cochlea of the inner ear. The unique dual mode of action of its small-molecule Kv7.4 activators combines acute functional OHC enhancement and sustained OHC protection and aims to both enhance and preserve a patient's natural hearing. Acousia Therapeutics develops drugs for both local and systemic administration.

Contact

Tim Boelke, M.D.
boelke@acousia.com
www.acousia.com

 

View original content:https://www.prnewswire.co.uk/news-releases/hearing-loss-company-acousia-announces-first-patient-enrolled-in-its-phase-2-prohear-study-302061818.html